T1	Participants 140 229	patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial
T2	Participants 495 511	myeloma patients
T3	Participants 796 858	628 patients who were eligible for the clinical protocol E9486
T4	Participants 29 45	multiple myeloma
T5	Participants 2843 2859	myeloma patients
T6	Participants 2921 2929	patients
